. 2023 Jun 24;68(2):213–226. doi: 10.1016/j.advms.2023.05.003

Table 2.

An Overview of the clinical development of DNA vaccines against SARS-CoV-2.

#	Type of Vaccine Candidate	Number of Doses	Route of administration	Developers	Clinical Trial Phase
1.	nCov vaccine	3	ID	Zydus Cadila	Phase 4
2.	INO-4800+electroporation	2	ID	Inovio Pharmaceuticals + International Vaccine Institute + Advaccine (Suzhou) Biopharmaceutical Co., Ltd	Phase 3
3.	AG0301-COVID19	2	IM	AnGes + Takara Bio + Osaka University	Phase 2/3
4.	GX-19 N	2	IM	Genexine Consortium	Phase 1/2
5.	GLS-5310	2	ID	GeneOne Life Science, Inc.	Phase 1/2
6.	COVID-eVax	2	IM	Takis + Rottapharm Biotech	Phase 1/2
7.	AG0302-COVID19	2–3	IM	AnGes Inc.	Phase 1/2
8.	VB10.2129	1–2	IM	Vaccibody AS	Phase 1/2
9.	VB10.2210	2	IM	Vaccibody AS	Phase 1/2
10.	Covigenix VAX-001	2	IM	Entos Pharmaceuticals Inc.	Phase 1
11.	CORVax 12	2	ID	Providence Health & Services	Phase 1
12.	bacTRL-Spike	1	Oral	Symvivo Corporation	Phase 1
13.	COVIGEN	2	ID or IM	University of Sydney, Bionet Co., Ltd Technovalia"	Phase 1
14.	COVIDITY	2	ID	Scancell Ltd	Phase 1
15.	SARS-CoV-2 DNA vaccine	2	IM	The University of Hong Kong; Immuno Cure 3 Limited	Phase 1
16.	Prophylactic pDNA Vaccine	3	IM	Imam Abdulrahman Bin Faisal University	Phase 1

Abbreviations: ID - Intradermal; IM - Intramuscular.